FI80830C - Förfarande för framställning av för farmaceutiskt bruk avsett, såsom a ktiv beståndsdel vid framställning av nya flernukleära järn(III)- blan dkomplex innehållande lösning - Google Patents
Förfarande för framställning av för farmaceutiskt bruk avsett, såsom a ktiv beståndsdel vid framställning av nya flernukleära järn(III)- blan dkomplex innehållande lösning Download PDFInfo
- Publication number
- FI80830C FI80830C FI833707A FI833707A FI80830C FI 80830 C FI80830 C FI 80830C FI 833707 A FI833707 A FI 833707A FI 833707 A FI833707 A FI 833707A FI 80830 C FI80830 C FI 80830C
- Authority
- FI
- Finland
- Prior art keywords
- iron
- solution
- iii
- preparation
- complex
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 22
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000004480 active ingredient Substances 0.000 title claims description 9
- 239000003814 drug Substances 0.000 title description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 83
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 39
- 229910052742 iron Inorganic materials 0.000 claims description 38
- 238000001256 steam distillation Methods 0.000 claims description 12
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000005292 vacuum distillation Methods 0.000 claims description 6
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 229940099563 lactobionic acid Drugs 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 57
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000013110 organic ligand Substances 0.000 description 9
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000001669 Mossbauer spectrum Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 150000004698 iron complex Chemical class 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 150000002506 iron compounds Chemical class 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000003926 complexometric titration Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Chemical group 0.000 description 1
- 239000001257 hydrogen Chemical group 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- -1 iron acetate anions Chemical class 0.000 description 1
- LNOZJRCUHSPCDZ-UHFFFAOYSA-L iron(ii) acetate Chemical compound [Fe+2].CC([O-])=O.CC([O-])=O LNOZJRCUHSPCDZ-UHFFFAOYSA-L 0.000 description 1
- WKPSFPXMYGFAQW-UHFFFAOYSA-N iron;hydrate Chemical compound O.[Fe] WKPSFPXMYGFAQW-UHFFFAOYSA-N 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU328182A HU187167B (en) | 1982-10-15 | 1982-10-15 | Process for producing pharmaceutical solution of new type polynuclear iron/iii/ mixed complex activity |
| HU328182 | 1982-10-15 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI833707A0 FI833707A0 (fi) | 1983-10-12 |
| FI833707A FI833707A (fi) | 1984-04-16 |
| FI80830B FI80830B (fi) | 1990-04-30 |
| FI80830C true FI80830C (sv) | 1990-08-10 |
Family
ID=10963435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI833707A FI80830C (sv) | 1982-10-15 | 1983-10-12 | Förfarande för framställning av för farmaceutiskt bruk avsett, såsom a ktiv beståndsdel vid framställning av nya flernukleära järn(III)- blan dkomplex innehållande lösning |
Country Status (11)
| Country | Link |
|---|---|
| AT (1) | AT385655B (sv) |
| BE (1) | BE897980A (sv) |
| BG (1) | BG49708A3 (sv) |
| DE (1) | DE3337506A1 (sv) |
| DK (1) | DK476583A (sv) |
| ES (1) | ES8406196A1 (sv) |
| FI (1) | FI80830C (sv) |
| FR (1) | FR2534589B1 (sv) |
| GB (1) | GB2129821B (sv) |
| HU (1) | HU187167B (sv) |
| SE (1) | SE462140B (sv) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3728814A1 (de) * | 1987-08-28 | 1989-03-30 | Lentia Gmbh | Loesung zur anwendung als spuelfluessigkeit in der zerstoerung von koerperfremden ablagerungen in menschlichen und tierischen geweben oder koerperhohlraeumen |
| DE4445772A1 (de) * | 1993-12-27 | 1995-06-29 | Loeser Thomas Dr Ing | Verfahren zur Ermittlung der Arzneimittelzusammensetzung |
| DE19712493A1 (de) * | 1997-03-25 | 1998-10-01 | Univ Karlsruhe | Pharmazeutische Zubereitung, enthaltend eine Eisen-Calcium-Polyolato-Verbindung und deren Verwendung |
| DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| US20040170724A1 (en) | 2003-02-28 | 2004-09-02 | Kraft Foods Holdings, Inc. | Mineral complexes of lactobionic acid and method of using for mineral fortification of food products |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE862482C (de) * | 1950-05-14 | 1953-01-12 | Merck Chem Fab E | Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens |
| DE938502C (de) * | 1953-02-27 | 1956-02-02 | Benger S Ltd | Verfahren zur Herstellung einer kolloidalen Eisenzubereitung |
| GB978485A (en) * | 1960-10-26 | 1964-12-23 | Astra Apotekarnes Kem Fab | Iron preparations for intramuscular injection |
| DE1293144B (de) * | 1964-11-04 | 1969-04-24 | Hausmann Ag Labor | Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid |
| DK122890B (da) * | 1964-12-29 | 1972-04-24 | J Reumert | Fremgangsmåde til fremstilling af ferrihydroxiddextrankomplekser. |
| DE1617463A1 (de) * | 1965-11-20 | 1971-04-08 | Bayer Ag | Verfahren zur Herstellung von injizierbaren kolloidalen Eisenzubereitungen |
| GB1149137A (en) * | 1966-10-28 | 1969-04-16 | H C F Porsche K G Ing | Screw outboard drive for boats |
| AT279048B (de) * | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
| DE2527158A1 (de) * | 1975-06-18 | 1976-12-23 | Herz Eberhard | Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin |
| JPS6039681B2 (ja) * | 1976-01-01 | 1985-09-07 | 日本臓器製薬株式会社 | デキストリン・クエン酸・第二鉄多核複合体及び該複合体を含有する非経口用鉄剤 |
| GB2006243B (en) * | 1977-09-29 | 1982-07-14 | Atomic Energy Authority Uk | Compounds |
| DE3026868C2 (de) * | 1980-07-16 | 1986-03-13 | Laboratorien Hausmann AG, St. Gallen | Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung |
-
1982
- 1982-10-15 HU HU328182A patent/HU187167B/hu not_active IP Right Cessation
-
1983
- 1983-10-12 AT AT363983A patent/AT385655B/de not_active IP Right Cessation
- 1983-10-12 FI FI833707A patent/FI80830C/sv not_active IP Right Cessation
- 1983-10-13 BE BE0/211691A patent/BE897980A/fr not_active IP Right Cessation
- 1983-10-14 DK DK476583A patent/DK476583A/da not_active Application Discontinuation
- 1983-10-14 SE SE8305665A patent/SE462140B/sv not_active IP Right Cessation
- 1983-10-14 ES ES526481A patent/ES8406196A1/es not_active Expired
- 1983-10-14 BG BG062649A patent/BG49708A3/xx unknown
- 1983-10-14 DE DE19833337506 patent/DE3337506A1/de active Granted
- 1983-10-14 GB GB08327633A patent/GB2129821B/en not_active Expired
- 1983-10-14 FR FR8316377A patent/FR2534589B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES526481A0 (es) | 1984-08-01 |
| FI833707A0 (fi) | 1983-10-12 |
| DK476583D0 (da) | 1983-10-14 |
| BG49708A3 (en) | 1992-01-15 |
| ATA363983A (de) | 1987-10-15 |
| FR2534589A1 (fr) | 1984-04-20 |
| DE3337506C2 (sv) | 1991-07-04 |
| SE462140B (sv) | 1990-05-14 |
| GB8327633D0 (en) | 1983-11-16 |
| BE897980A (fr) | 1984-01-30 |
| GB2129821B (en) | 1986-02-19 |
| DK476583A (da) | 1984-04-16 |
| FI833707A (fi) | 1984-04-16 |
| FR2534589B1 (fr) | 1988-12-16 |
| SE8305665D0 (sv) | 1983-10-14 |
| GB2129821A (en) | 1984-05-23 |
| ES8406196A1 (es) | 1984-08-01 |
| HU187167B (en) | 1985-11-28 |
| AT385655B (de) | 1988-05-10 |
| FI80830B (fi) | 1990-04-30 |
| DE3337506A1 (de) | 1984-04-19 |
| SE8305665L (sv) | 1984-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Finnegan et al. | Neutral water-soluble post-transition-metal chelate complexes of medical interest: aluminum and gallium tris (3-hydroxy-4-pyronates) | |
| US5883088A (en) | Solid dosage forms for the oral administration of gallium | |
| EP0057023B1 (en) | Novel platinum complexes | |
| JP6655617B2 (ja) | Ｇｄ−ＤＯＴＡ金属錯体のメグルミン塩を含む製剤 | |
| CA1253803A (en) | Buccal and nasal compositions containing iron complexes of 3-hydroxy-4-pyrones | |
| JPH082855B2 (ja) | 新規磁気共鳴造影剤 | |
| FI78837C (sv) | Förfarande för framställning av en för injektionsadministration lämpli g, stabil och saltsyrahaltig vattenlösning av cis-platina | |
| US5258376A (en) | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones | |
| BR112017010867B1 (pt) | Métodos para preparação de uma formulação farmacêutica líquida e para preparação de um agente de contraste para formação de imagem de ressonância magnética, quelante sequestrante ligado a uma fase sólida, e, uso de um quelante sequestrante ligado a uma fase sólida | |
| FI80830C (sv) | Förfarande för framställning av för farmaceutiskt bruk avsett, såsom a ktiv beståndsdel vid framställning av nya flernukleära järn(III)- blan dkomplex innehållande lösning | |
| JPS595599B2 (ja) | プラチナ有機錯体、その製法および該錯体よりなる悪性腫瘍治療剤 | |
| JPH0780764B2 (ja) | 新生物形成病用医薬組成物 | |
| Talwar et al. | Influence of aluminum on mineralization during matrix–induced bone development | |
| Terato et al. | Studies on iron absorption: I. The role of low molecular polymer in iron absorption | |
| CA2053478C (en) | Magnetic resonance imaging agent | |
| JP3040462B2 (ja) | 新規磁気共鳴法造影剤 | |
| EP1043316B1 (en) | Nitroimidazole derivatives as sensitivity enhancers for chemotherapy and radiotherapy | |
| Gómez et al. | Aluminium distribution and excretion: a comparative study of a number of chelating agents in rats | |
| JPH0629191B2 (ja) | 抗腫瘍剤、抗ウィルス剤 | |
| CN105520955B (zh) | 一种羧基麦芽糖铁药用组合物及其制备方法 | |
| Brubaker et al. | Mixed-ligand complexes of cobalt (III). Chelated (amino acid)(tetramine) cobalt (III) complexes | |
| JPH01259850A (ja) | Ｍｎ（ＩＩ）配位組成物を使用するＮＭＲ像形成 | |
| Lote et al. | Effect of citrate on plasma aluminium concentration and aluminium excretion in the rat | |
| KR100650090B1 (ko) | 인 함유 에틸렌디아민 유도체의 칼슘 착체 | |
| JPS59116221A (ja) | 白金またはパラジウム錯体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: RICHTER GEDEON VEGYESZETI GYAR R.T. |